Natco v Bayer: India’s First Compulsory Licence Explained

Natco v Bayer is the case in which India’s Controller of Patents granted a compulsory licence on 9 March 2012,…

Natco v Bayer is the case in which India’s Controller of Patents granted a compulsory licence on 9 March 2012, allowing Natco Pharma to make and sell a generic version of Bayer’s cancer drug Nexavar (sorafenib tosylate) without Bayer’s consent. An appeal, a writ petition and a Supreme Court petition left the licence in place.

The case arose under Section 84 of India’s Patents Act, 1970, which lets any interested person seek a compulsory licence three years after a patent is granted. The application, Natco Pharma Ltd v Bayer Corporation, C.L.A. No. 1 of 2011, concerned Indian Patent No. 215758. The Intellectual Property Appellate Board (IPAB) described the grant as the first compulsory licence made in India (IPAB, para 57).

Quick answer: The Controller found all three Section 84 grounds made out and fixed a 6% royalty. The IPAB raised it to 7% and held that import can count as working only where the patentee proves why it could not manufacture in India. The Bombay High Court agreed in 2014, and the Supreme Court declined to interfere, keeping all questions of law open.

How did the Natco v Bayer dispute begin?

Bayer’s patent on sorafenib tosylate was granted on 3 March 2008. Bayer sold the drug at about Rs 2,80,428 for a month’s therapy. Natco asked Bayer for a voluntary licence on 6 December 2010, Bayer refused on 27 December 2010, and Natco applied for a compulsory licence on 29 July 2011.

Natco’s letter offered to sell the drug at less than Rs 10,000 a month if licensed (IPAB, para 14). Bayer’s reply stated that it did not “consider it appropriate, to grant voluntary licence” (IPAB, para 12). By then Bayer had sued Cipla for infringement in 2010 and had sued Natco in the Delhi High Court in May 2011 (IPAB, para 3). The pending Natco suit did not stop the compulsory licence case: the Controller refused Bayer’s petition to stay it on that ground on 27 October 2011 (Controller’s order, p. 7).

Bayer’s import volumes and Natco’s proposed price were central to the application. Bayer had obtained permission to import and market the drug in India by January 2008, yet imported only small quantities in 2009 and 2010 (IPAB, para 47). And Natco proposed to sell at Rs 74 a tablet, which the order records as Rs 8,800 a month (Controller’s order, pp. 6 and 55). The Controller found a prima facie case on 9 August 2011 and directed Natco to serve the application on Bayer (p. 6).

What did the Controller order in March 2012?

The Controller of Patents, P.H. Kurian, granted Natco a non-exclusive licence after finding all three grounds in Section 84(1): the public’s reasonable requirements were not met, the drug was not available at a reasonably affordable price, and the invention was not worked in India. Natco was to pay Bayer 6% of net sales.

The supply figures were stark. Bayer put the patients needing the drug at 8,842 a year, yet sold 593 boxes in 2011, enough for about 200 patients (Bombay High Court, para 13(c)). On working, the Controller took the strictest view of the three forums. Reading Section 83, which states that patents are not granted merely to give patentees an import monopoly, he held that “mere importation cannot amount to working of a patented invention” and that working implies manufacture in India to a reasonable extent (Controller’s order, p. 43). He also refused Bayer’s request for more time under Section 86, treating its patient assistance proposals as philanthropy rather than steps to work the invention on a commercial scale (p. 55).

On royalty, Bayer had asked for 15% of net sales, payable in US dollars (p. 57). Bayer cited about EUR 1.8 billion of research spending, which the Controller noted covered the five years before 2010. He could not fix the actual cost of this invention, though he accepted that Bayer had spent a considerable sum (p. 59). Citing a UNDP guideline of 4%, adjustable by up to 2% either way, he fixed 6% (p. 60).

Licence termWhat the order says (clause 15)
PriceNot more than Rs 8,880 for a pack of 120 tablets, one month’s treatment
Royalty6% of net sales, paid quarterly (raised to 7% by the IPAB)
ReportingQuarterly sales accounts to the Controller and to Bayer
Free supplyAt least 600 needy and deserving patients a year, reported by affidavit each January
ScopeTreating liver and kidney cancer (HCC and RCC) in humans, within India only
ManufactureOnly at Natco’s own facility; no outsourcing and no right to import
NatureNon-exclusive and non-assignable, for the balance term of the patent
Branding and liabilityNatco’s product, name and packaging visibly distinct; no support from Bayer; Natco solely liable for its product
CompetitionBayer free to compete and to license others to compete

The two price figures are easily confused. At Rs 74 a tablet, 120 tablets come to Rs 8,880, which is the cap the operative clause adopts (Controller’s order, p. 60, clause 15(a)). The licence ran only for the balance of the patent’s term, and that term, counted under Section 53 from the international filing date of 12 January 2000, could not run beyond twenty years.

How did the IPAB change the reasoning?

On 4 March 2013 the IPAB, chaired by Justice Prabha Sridevan, confirmed the licence and dismissed Bayer’s appeal except on royalty, which it raised by one percentage point to 7%. It differed from the Controller on two points: whether importing the patented product could satisfy the working requirement, and whether a price cut after the application can count.

The Board held that “working” has a flexible meaning and must be decided case by case. Import alone may suffice in a given case, but “the patentee must show why it could not be locally manufactured. A mere statement to that effect is not sufficient there must be evidence” (IPAB, para 52). Even qualifying imports must be on a commercial scale, to an adequate extent and at a reasonably affordable price (para 41).

Bayer had a manufacturing facility in India and gave no such evidence (para 52). Its Form 27 filed in 2010 showed only patient support packs imported, and in 2010 not one commercial pack was imported (paras 46 and 47).

On later measures, the Controller had read the closing words of Section 84(6) as barring him from considering anything the patentee did after the application (Controller’s order, p. 54). The Board said those words are “not an absolute taboo”. Speaking hypothetically, it reasoned that a patentee which permanently brought its price down to a reasonably affordable level while the case was pending would not be frustrating the proceedings (paras 43 and 44). It still upheld the Controller’s conclusion, as Bayer had not done that.

The Board rejected Bayer’s other grounds in turn:

  • The patentee was not entitled to a hearing before the Controller’s prima facie decision under Section 87(1); the hearing comes after opposition (para 9).
  • Natco’s letter met the requirement to seek a voluntary licence first: the offer was made and rejected (paras 12 to 16).
  • The three grounds are alternatives, so one is enough (para 39).
  • Cipla’s sales could not count. Bayer was suing Cipla as an infringer, and the conditions must be judged “with reference to the patentee alone and not a party whose presence itself is litigious” (para 29).
  • Patient assistance programmes do not meet the affordability ground, which looks at the price the public pays (para 42).
  • Refusing Bayer more time under Section 86 was within the Controller’s discretion. The Board asked Bayer’s counsel whether the request was a tacit admission of non-working; counsel said it was made without prejudice (paras 48 and 49).

On royalty, the Board noted that distributors and stockists took a margin of about 30% while Bayer received 6%, and that Natco’s own margin was roughly 14%. It kept the royalty on net sales rather than on Natco’s margin and added one percentage point (para 54).

The Board also dealt with conduct on both sides. Natco’s application had stated that it held a process patent which had in fact not been granted, and the Board directed it to pay Rs 50,000 in costs to Tata Memorial Cancer Hospital, Mumbai, for poor patients (para 56). Bayer had argued that Natco’s first free-supply affidavit, covering 313 patients against a pro rata 450, justified revoking the licence. The Board left Bayer to approach the Controller “if permitted in law” (para 55). The licence itself contains no breach or termination clause; Bayer’s proposed term making a failure to supply free drug a material breach was not adopted (Controller’s order, pp. 57 and 60 to 62).

What did the Bombay High Court add?

A Division Bench of Chief Justice Mohit S. Shah and Justice M.S. Sanklecha dismissed Bayer’s writ petition (under Article 226) on 15 July 2014. It upheld the 7% royalty and the IPAB’s reading of working, and added guidance on burden of proof, supply of medicines and affordable price.

On the voluntary licence, Bayer argued that its reply had left a window open for Natco. The court found that window “illusory”, since it invited Natco only to add to its existing request (para 12). On burden, the applicant must make out a prima facie case; the patentee must then lead evidence that public requirements are met (para 13(a)). For medicines, the court held, adequate supply means “100% i.e. to the fullest extent” (para 13(f)).

On Cipla, the court found demand unmet even after adding Cipla’s 4,686 packs to Bayer’s supply (para 13(c)). It held that an infringer’s supply can count only where the patentee accepts its participation and in effect grants it a de facto licence (para 13(d)).

On price, the court held that the Act gives the Controller no power to investigate prices, so affordability is decided on the parties’ evidence. Bayer’s price, which the court put at about Rs 2,84,000 a month, set against Natco’s Rs 8,800, by itself showed that Bayer’s price was not reasonably affordable (para 14(a)). Bayer had objected to the Controller calling for its balance sheet and at no stage produced its drug-specific research costs or its US orphan-drug reimbursement, so the court drew an adverse inference (paras 14(b) and 14(c)).

The court treated Bayer’s patient assistance price as conditional “charity”, not a price open to the public, so it could not meet the affordability ground (para 14(d)). It accepted that differential pricing may help a patentee show that the public’s reasonable requirements are met, a separate ground (para 14(e)).

On working, the court agreed with the Board that manufacture is not necessary in every case. The patentee “would nevertheless have to satisfy the authorities” why it was not manufacturing in India, establishing reasons that make manufacture in India “impossible/ prohibitive”; if it does, import can count as working (para 15(b)). The court rejected the Government’s argument that working always means local manufacture. It also upheld the refusal of more time under Section 86, as Bayer led no evidence of prompt steps to work the patent after 2008 (para 16).

What did the Supreme Court decide?

On 12 December 2014 a bench of Justices Ranjan Gogoi and Rohinton Fali Nariman dismissed Bayer’s special leave petition (a request for permission to appeal), SLP (C) No. 30145 of 2014. The order is two sentences long and decides no question of law. The reasoned rulings on Section 84 therefore remain those of the High Court and the IPAB.

The order reads: “In the facts of the present case, we are not inclined to interfere. The Special Leave Petition is dismissed, keeping all questions of law open.” The last clause matters. The dismissal left the Bombay High Court judgment undisturbed without deciding the questions of law, including the meaning of “working”, “reasonably affordable price” and “adequate extent”. That judgment remains the highest reasoned ruling in this litigation; the Supreme Court did not decide those questions on the merits.

How did the United States respond?

The United States Trade Representative’s annual Special 301 Reports for 2012, 2013 and 2014 each flagged concern about compulsory licensing in India, and the 2013 and 2014 reports criticised the reasoning directly. India was already on the Priority Watch List, the reports’ list of countries of particular concern, and remained on it in each year.

The 2012 report said the US would closely monitor compulsory licensing in India following “the broad interpretation of Indian law” in the Controller’s decision, while bearing in mind the Doha Declaration on TRIPS and Public Health. The 2013 report applied similar language to the IPAB decision. It described restricting a patentee’s rights partly because it imported rather than manufactured in India as “a troubling precedent”, and said the reasoning could reach sectors beyond pharmaceuticals, such as green technology and information and communications technology.

The 2014 report, which also announced an Out-of-Cycle Review of India’s intellectual property record generally (a further assessment outside the annual cycle), noted that the IPAB had modified the Controller’s reasoning so that working could in some cases be met by import. It objected that the Board had not clarified when that would be so, and urged India to be transparent about government-initiated compulsory licences it was considering. It recorded that India had issued only one compulsory licence under Section 84.

The Indian forums addressed the international rules directly. The IPAB relied on the TRIPS Agreement’s case-by-case approach to authorising compulsory licences (para 52). The High Court held that Bayer’s reliance on Article 27 of TRIPS ignored the exceptions in Articles 30 and 31 (para 15(b)). It also cited the Doha Declaration on access to medicines (para 13(f)). For background on WIPO and the WTO’s TRIPS Agreement, see our guide to the differences between WIPO and TRIPS.

What does Natco v Bayer mean for patentees today?

For a patent holder in India, the decisions show the evidence required to address each Section 84 ground. Show working with real commercial supply, keep documented reasons if the product is not made in India, and treat a voluntary licence request as a negotiation on terms. Price the product for the public, not only for assistance schemes.

Keep separate records of commercial supply and of the reasons for relying on imports, because the current form asks only whether each patent is worked, with no supply figures, and will not by itself show working on a commercial scale to an adequate extent. Under Rule 131(2) as amended in 2024, Form 27 is filed once for each period of three financial years, starting with the financial year after the one in which the patent was granted, within six months after the period ends; the proviso to Rule 131(2) lets the Controller extend this or condone delay by up to three months on Form 4. Rule 138 separately lets the Controller extend time or condone delay by up to six months, on a Form 4 request made within that period.

A note to the form requires every patentee and every licensee to file it. The current form records whether each patent is worked, the reasons if it is not, and whether it is available for licensing; it carries no supply figures. Its second note states that, subject to the Act’s conditions, a patent is not treated as not worked merely because the product is imported. Our note on the statement of working of patents explains the form.

A patentee that relies on imports should keep evidence of why manufacture in India is impossible or prohibitive (Bombay High Court, para 15(b)). The IPAB held that a mere statement is not enough (para 52), and that imports must still be on a commercial scale, to an adequate extent and at a reasonably affordable price (para 41). The IPAB’s reasoning leaves room to argue that a permanent cut in the public price while the case is pending should be considered, but the Board put this hypothetically, and Section 84(6) still provides that the Controller is not required to consider later matters (IPAB, para 43). Asking for more time under Section 86 without evidence of prompt steps is unlikely to help.

Except in the cases covered by the proviso, an applicant should be ready to show its efforts to obtain a voluntary licence. Section 84(6)(iv) asks whether the applicant made efforts to obtain a licence on reasonable terms and those efforts were not successful within a reasonable period “as the Controller may deem fit”; its Explanation reads that period as ordinarily not more than six months. The step does not apply in a national emergency, extreme urgency, public non-commercial use, or where anti-competitive practices by the patentee are established. A flat refusal, as here, lets the applicant show it tried.

Sections 94 and 85 address termination of the licence and possible revocation of the patent. The patentee may apply under Section 94 to end it, and the Controller may do so if “the circumstances that gave rise to the grant thereof no longer exist and such circumstances are unlikely to recur”; the licensee may object, and its interest must not be unduly prejudiced. Two years after the first compulsory licence, the Central Government or any person interested may apply under Section 85 to revoke the patent itself on the same three grounds. This is discussed in our article on patent revocation in India.

The forum has also changed. The IPAB was abolished by the Tribunals Reforms Act, 2021 with effect from 4 April 2021, and Section 117A now sends appeals from compulsory licence orders to the High Court. For how these provisions sit within the Act as a whole, see our overview of patent law in India.

Frequently Asked Questions

Yes. The IPAB described the Controller’s order of 9 March 2012 as the order of compulsory licence made in India for the first time. The 2014 US Special 301 Report likewise recorded that India had issued only one compulsory licence under Section 84 of the Patents Act at that point.

The Controller fixed the royalty at 6% of Natco’s net sales of the drug, payable quarterly. On appeal, the IPAB increased it by one percentage point to 7% of net sales and left the other terms unchanged. The Bombay High Court upheld the 7% rate, noting that Bayer led no evidence of its development costs.

The IPAB and the Bombay High Court held that working is decided case by case. Import may count where the patentee proves why manufacture in India is impossible or prohibitive, and the imports reach the public on a commercial scale, to an adequate extent and at a reasonably affordable price. The current Form 27 adds that, subject to the Act, importing alone does not make a patent not worked.

No. On 12 December 2014 the Supreme Court dismissed Bayer’s special leave petition in a brief two-sentence order. It said it was not inclined to interfere on the facts and expressly kept all questions of law open. The Bombay High Court judgment, left undisturbed, remains the highest reasoned ruling in the case.

The IPAB held that the Section 84 conditions must be judged with reference to the patentee alone, as Bayer was suing Cipla as an infringer. The Bombay High Court added that demand was unmet even counting Cipla’s 4,686 packs, and that an infringer’s supply counts only where the patentee accepts it as a de facto licensee.

No. The order granted the licence only for the balance term of the patent. Under Section 53, subject to the Act, a patent filed through the Patent Cooperation Treaty runs for twenty years from its international filing date, here 12 January 2000. The licence therefore could not run beyond January 2020, and would end earlier if the patent lapsed.

Intepat IP’s patent team verifies the status, recorded licences and renewal dates of patent holdings in India through its patent portfolio audit service.

This article explains the law on compulsory licensing under Section 84 in India as at October 2026 and is for general information only. It is not legal advice. Government fees, forms, and procedures change; confirm current figures with the Indian Patent Office before you file. For advice on your specific invention, consult a registered patent agent. This analysis is based on the full text of the decision cited; it is a summary for general information and not a substitute for reading the order in your own matter. Verified as of 23 October 2026.